Pakistan’s election oversight body said Thursday that parliamentary elections must be delayed because it needs four months to redraw constituencies to reflect the recently held census. A delay would likely heighten the political strains in Pakistan, which has seen now opposition leader Imran Khan removed as prime minister by a no-confidence vote by parliament in April 2022 and his imprisonment this year after a graft conviction. In a statement, the Election Commission of Pakistan said it won’t be able to complete drawing new constituencies before Dec. 14. That means the vote could possibily be delayed at least until February. The development came a week after President Arif Alvi dissolved parliament at the completion of its five-year term. Usually, that step starts the process of holding elections for a new parliament within 90 days. But elections could still be held later this year if the caretaker government, which was installed under Premier Anwaar-ul-Haq Kakar this week, decides to go ahead with it under the previous census. Kakar had no immediate comment on the announcement by the election oversight body. Analysts said the judiciary could also push Kakar’s government to hold the vote on time to meet the constitutional requirement. Under the constitution, a vote was to be held either in October or November. Kakar’s new Cabinet was sworn in Thursday at the Presidency in the capital, Islamabad. Kakar has chosen former diplomat Jalil Abbas Jilani to head the foreign ministry, and longtime journalist Murtaza Solangi to be the information minister. Khan's Pakistan Tehreek-e-Insaf opposition party is hoping to return to power after what is expected to be a close election. Khan, a highly popular 70-year-old former cricket star, has been held at the Attock prison in eastern Punjab province since Aug. 6, when he was sentenced to three years in prison by a court after being convicted of concealing assets he amassed by selling state gifts. A court in Islamabad will take up Khan's appeal next week, and his legal team is expecting him to be released. Khan will not be able to run in the election unless his conviction is overturned. Pakistan bars anyone with a criminal conviction of leading a political party, running in elections or holding public office. Read More Ukraine war’s heaviest fight rages in east - follow live Charity boss speaks out over ‘traumatic’ encounter with royal aide

The director of New York's Metropolitan Museum of Art said Thursday the famed institution would return more pieces of art to countries that were victims of looting as it joins...

'If they had been subjected to horrific conduct by Lizzo as claimed in the lawsuit, why would they choose to return?' questioned Lizzo's attorney

Sabato De Sarno wants people to fall in love with Gucci again, titling his debut collection “Gucci Ancora,” Italian for “Gucci Again.”

By David Brunnstrom and Michael Martina WASHINGTON A U.S. summit with Japan and South Korea on Friday will

In October, catch this special type of solar eclipse that occurs only once every year or two.

Horse racing will resume in September at Churchill Downs, home of the Kentucky Derby, the racetrack said Monday, after safety changes following the deaths of 12 horses within...

The Negro River, the Amazon's second largest tributary, has reached its lowest level since official measurements began near Manaus 121 years ago

WASHINGTON Democratic U.S. Senator Joe Manchin on Thursday announced that he will not seek re-election in 2024. "I

Taiwan cut its 2023 growth outlook for a second straight quarter, with the deteriorating economic situation likely to

A treatment for acute migraines has been approved for NHS use for the first time, with experts saying the move could be a “step-change” for thousands of people who suffer from the condition. The National Institute for Health and Care Excellence (Nice) said its final draft guidance on Rimegepant “addresses the high unmet need for treatment options for acute migraine”. Rimegepant, also known as Vydura and made by Pfizer, will be available to adults who have tried at least two triptans – medication usually given to tackle headaches or migraines – but found they did not work well enough. It can also be administered to those who are not able to take triptans or have an intolerance, or patients who have tried nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol. Helen Knight, director of medicines evaluation at Nice, said: “Migraine is a condition described in comments to Nice from carers and people with migraine as an invisible disability that affects all aspects of life including work, education, finances, mental health, social activities and family. “Today’s final draft guidance addresses the high unmet need for treatment options for acute migraine, once again demonstrating our ability to ensure clinically and cost-effective medicines are available to those who need them as quickly as possible.” Rimegepant is taken as a wafer, which dissolves under the tongue and works by stopping the release of a protein around the brain called calcitonin gene-related peptide. In July, the medicine was recommended as an option for preventing episodic migraines in adults who have at least four and fewer than 15 attacks per month if “at least” three other treatments have not worked. This is the first and only Nice-recommended medicine that can help alleviate the misery of acute migraines, and may be considered a step-change in treatment Helen Knight, Nice Under the latest guidance, it will also be used to relieve symptoms of a migraine, which can include pain, nausea and sensitivity to light, but also painless symptoms such as temporary visual disturbances known as “aura”, which Nice said “is not well managed with existing treatments”. The recommendation is expected to benefit about 13,000 people. Ms Knight added: “This is the first and only Nice-recommended medicine that can help alleviate the misery of acute migraines, and may be considered a step-change in treatment.” Migraine is an incredibly misunderstood condition that can have a significant impact on all areas of life, including ability to work, maintain relationships and mental health Robert Music, The Migraine Trust Robert Music, chief executive of The Migraine Trust, said the Nice guidance “provides people with migraine valuable options to help reduce the pain and length of a migraine attack”. “It brings new hope,” he added. “It will especially benefit those who have not found a treatment that works, those who get debilitating side effects – including medicine overuse headache – from them, and those with cardiovascular disease who cannot take existing treatments. “Migraine is an incredibly misunderstood condition that can have a significant impact on all areas of life, including ability to work, maintain relationships and mental health.” Read More NHS winter resilience fund announced by Government NHS reliance on paper notes ‘stopping trusts from realising full potential’ Recession fears as UK economy shrinks by more than expected in shock decline Charity boss speaks out over ‘traumatic’ encounter with royal aide Ukraine war’s heaviest fight rages in east - follow live

Internet gushes over ‘GMA’ host Ginger Zee’s simple glam look